Radiology Department, Hospital Lucus Augusti Lugo, Ulises Romero 1, Lugo, 27003, Spain.
Nuclear Medicine Department and Molecular Imaging Group, Complexo Hospitalario Universitario de Santiago de Compostela CHUS-IDIS, Travesía da Choupana s/n, Santiago de Compostela, 15706, Spain.
Eur J Radiol. 2018 Nov;108:201-207. doi: 10.1016/j.ejrad.2018.10.001. Epub 2018 Oct 2.
To evaluate the diagnostic value of dedicated breast PET (dbPET) parallel imaging in mammographically or sonographically detected BI-RADS 4 (Breast Imaging Reporting And Data Systems) lesions.
After institutional review board and patient approvals, 50 consecutive women with 60 BI-RADS 4 breast lesions were prospectively included in the study. All patients underwent Magnetic Resonance Imaging (MRI) and dbPET before biopsy and fusion of both MRI and dbPET images was performed to better locate corresponding lesions. Final findings were compared with histological results. Sensitivity and specificity for dbPET were determined along with their respective 95%-confidence intervals.
Histopathology examination revealed 18 malignant lesions (7 in situ and 11 invasive carcinomas) and 42 benign entities. The dedicated breast PET reported no evidence of malignancy in 41 patients, 9 of them with histological diagnosis of neoplasm. Besides, dbPET showed increased metabolically activity in 10 benign lesions and in 9 breast cancers. Two invasive carcinomas were located less than 1 cm from the pectoral muscle, which can explain that they were missed by dbPET because they were outside the field of view (FOV). There were other 6 false negative results, which corresponded to a 0.1 cm invasive lobular carcinoma and 5 in situ carcinomas. Sensitivity and specificity of dbPET were 50% and 76%, respectively.
Our analysis does not allow the recommendation of dbPET for diagnosis of malignancy in BI-RADS 4 mammographic or US abnormalities, mainly due to its high false-negative rate for the detection of in situ carcinomas (85.7%). However, considering the lesions greater than 0.1 cm and included in the FOV, dbPET depicted all invasive carcinomas.
评估专用乳腺 PET(dbPET)并行成像在乳腺或超声检测到 BI-RADS 4(乳腺影像报告和数据系统)病变中的诊断价值。
在机构审查委员会和患者批准后,前瞻性纳入 50 名连续患有 60 个 BI-RADS 4 乳腺病变的女性患者。所有患者均在活检前行 MRI 和 dbPET 检查,并对 MRI 和 dbPET 图像进行融合,以更好地定位相应病变。最终结果与组织学结果进行比较。确定 dbPET 的敏感性和特异性及其各自的 95%置信区间。
组织病理学检查显示 18 例恶性病变(7 例原位癌和 11 例浸润性癌)和 42 例良性病变。专用乳腺 PET 在 41 名患者中报告无恶性证据,其中 9 名患者的组织学诊断为肿瘤。此外,dbPET 显示 10 个良性病变和 9 个乳腺癌的代谢活性增加。2 例浸润性癌距离胸肌不到 1cm,这可以解释为什么 dbPET 未能检测到它们,因为它们超出了视野(FOV)。还有其他 6 个假阴性结果,对应于 1 个 0.1cm 的浸润性小叶癌和 5 个原位癌。dbPET 的敏感性和特异性分别为 50%和 76%。
我们的分析不允许推荐 dbPET 用于诊断 BI-RADS 4 乳腺或 US 异常中的恶性肿瘤,主要是因为它对原位癌的检测具有很高的假阴性率(85.7%)。然而,考虑到大于 0.1cm 且包含在 FOV 中的病变,dbPET 描绘了所有浸润性癌。